Global Gynecological Cancers Therapeutics Market 2024-2028

Description

List of Tables

The gynecological cancers therapeutics market is forecasted to grow by USD 19.15 bn during 2023-2028, accelerating at a CAGR of 15.83% during the forecast period. The report on the gynecological cancers therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of gynecological cancers, strong pipeline and new drug approvals, and rising number of patient assistance programs.

Technavio's gynecological cancers therapeutics market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	13.17%
CAGR	15.83%
Incremental Value	$19.15bn

By Type

Uterine cancer
Ovarian cancer
Cervical cancer
Others

By Modality

Chemotherapy
Targeted therapy
Hormonal therapy

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the emergence of novel therapies as one of the prime reasons driving the gynecological cancers therapeutics market growth during the next few years. Also, availability of advanced diagnostic modalities and rising awareness of gynecological cancers will lead to sizable demand in the market.

The report on the gynecological cancers therapeutics market covers the following areas:

Gynecological cancers therapeutics market sizing
Gynecological cancers therapeutics market forecast
Gynecological cancers therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gynecological cancers therapeutics market vendors that include AbbVie Inc., Amgen Inc., Apotex Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Cipla Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Hikma Pharmaceuticals Plc, Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the gynecological cancers therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR73551

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Modality
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global gynecological cancers therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global gynecological cancers therapeutics market 2018 - 2022 ($ billion)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.3 Modality Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Modality Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Uterine cancer - Market size and forecast 2023-2028
Exhibit 34: Chart on Uterine cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Uterine cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Uterine cancer - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Uterine cancer - Year-over-year growth 2023-2028 (%)
6.4 Ovarian cancer - Market size and forecast 2023-2028
Exhibit 38: Chart on Ovarian cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Ovarian cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Ovarian cancer - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Ovarian cancer - Year-over-year growth 2023-2028 (%)
6.5 Cervical cancer - Market size and forecast 2023-2028
Exhibit 42: Chart on Cervical cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Cervical cancer - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Cervical cancer - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Cervical cancer - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Type
Exhibit 50: Market opportunity by Type ($ billion)
Exhibit 51: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Modality

7.1 Market segments
Exhibit 52: Chart on Modality - Market share 2023-2028 (%)
Exhibit 53: Data Table on Modality - Market share 2023-2028 (%)
7.2 Comparison by Modality
Exhibit 54: Chart on Comparison by Modality
Exhibit 55: Data Table on Comparison by Modality
7.3 Chemotherapy - Market size and forecast 2023-2028
Exhibit 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
7.4 Targeted therapy - Market size and forecast 2023-2028
Exhibit 60: Chart on Targeted therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Targeted therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Targeted therapy - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Targeted therapy - Year-over-year growth 2023-2028 (%)
7.5 Hormonal therapy - Market size and forecast 2023-2028
Exhibit 64: Chart on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Hormonal therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Hormonal therapy - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Hormonal therapy - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Modality
Exhibit 68: Market opportunity by Modality ($ billion)
Exhibit 69: Data Table on Market opportunity by Modality ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 119: AbbVie Inc. - Overview
Exhibit 120: AbbVie Inc. - Product / Service
Exhibit 121: AbbVie Inc. - Key news
Exhibit 122: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 123: Amgen Inc. - Overview
Exhibit 124: Amgen Inc. - Product / Service
Exhibit 125: Amgen Inc. - Key offerings
12.5 Apotex Inc.
Exhibit 126: Apotex Inc. - Overview
Exhibit 127: Apotex Inc. - Product / Service
Exhibit 128: Apotex Inc. - Key offerings
12.6 AstraZeneca Plc
Exhibit 129: AstraZeneca Plc - Overview
Exhibit 130: AstraZeneca Plc - Product / Service
Exhibit 131: AstraZeneca Plc - Key news
Exhibit 132: AstraZeneca Plc - Key offerings
12.7 Bayer AG
Exhibit 133: Bayer AG - Overview
Exhibit 134: Bayer AG - Business segments
Exhibit 135: Bayer AG - Key news
Exhibit 136: Bayer AG - Key offerings
Exhibit 137: Bayer AG - Segment focus
12.8 Bristol Myers Squibb Co.
Exhibit 138: Bristol Myers Squibb Co. - Overview
Exhibit 139: Bristol Myers Squibb Co. - Product / Service
Exhibit 140: Bristol Myers Squibb Co. - Key news
Exhibit 141: Bristol Myers Squibb Co. - Key offerings
12.9 Cipla Ltd.
Exhibit 142: Cipla Ltd. - Overview
Exhibit 143: Cipla Ltd. - Business segments
Exhibit 144: Cipla Ltd. - Key news
Exhibit 145: Cipla Ltd. - Key offerings
Exhibit 146: Cipla Ltd. - Segment focus
12.10 Eli Lilly and Co.
Exhibit 147: Eli Lilly and Co. - Overview
Exhibit 148: Eli Lilly and Co. - Product / Service
Exhibit 149: Eli Lilly and Co. - Key news
Exhibit 150: Eli Lilly and Co. - Key offerings
12.11 F. Hoffmann La Roche Ltd.
Exhibit 151: F. Hoffmann La Roche Ltd. - Overview
Exhibit 152: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 153: F. Hoffmann La Roche Ltd. - Key news
Exhibit 154: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 155: F. Hoffmann La Roche Ltd. - Segment focus
12.12 GlaxoSmithKline Plc
Exhibit 156: GlaxoSmithKline Plc - Overview
Exhibit 157: GlaxoSmithKline Plc - Business segments
Exhibit 158: GlaxoSmithKline Plc - Key news
Exhibit 159: GlaxoSmithKline Plc - Key offerings
Exhibit 160: GlaxoSmithKline Plc - Segment focus
12.13 Hikma Pharmaceuticals Plc
Exhibit 161: Hikma Pharmaceuticals Plc - Overview
Exhibit 162: Hikma Pharmaceuticals Plc - Business segments
Exhibit 163: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 164: Hikma Pharmaceuticals Plc - Segment focus
12.14 Merck and Co. Inc.
Exhibit 165: Merck and Co. Inc. - Overview
Exhibit 166: Merck and Co. Inc. - Business segments
Exhibit 167: Merck and Co. Inc. - Key news
Exhibit 168: Merck and Co. Inc. - Key offerings
Exhibit 169: Merck and Co. Inc. - Segment focus
12.15 Novartis AG
Exhibit 170: Novartis AG - Overview
Exhibit 171: Novartis AG - Business segments
Exhibit 172: Novartis AG - Key offerings
Exhibit 173: Novartis AG - Segment focus
12.16 Pfizer Inc.
Exhibit 174: Pfizer Inc. - Overview
Exhibit 175: Pfizer Inc. - Product / Service
Exhibit 176: Pfizer Inc. - Key news
Exhibit 177: Pfizer Inc. - Key offerings
12.17 Sanofi SA
Exhibit 178: Sanofi SA - Overview
Exhibit 179: Sanofi SA - Business segments
Exhibit 180: Sanofi SA - Key news
Exhibit 181: Sanofi SA - Key offerings
Exhibit 182: Sanofi SA - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 183: Inclusions checklist
Exhibit 184: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 185: Currency conversion rates for US$
13.4 Research methodology
Exhibit 186: Research methodology
Exhibit 187: Validation techniques employed for market sizing
Exhibit 188: Information sources
13.5 List of abbreviations
Exhibit 189: List of abbreviations